The role of metabolic variables of serum uric acid beyond polycystic ovary syndrome (PCOS) phenotypes Authors: Megha Haresh Raheja Published: 2026 Sir, I read with considerable interest the recent study1 on serum uric acid levels in patients with different phenotypes of polycystic ovary syndrome (PCOS) published in the December 2025 issue of the Indian Journal of Medical Research.1 The authors indicate that phenotype A (classic hyperandrogenic phenotype) had a higher serum uric acid than controls and some other phenotypes, and they deduce that phenotype can affect uric acid levels. Although this observation is significant, the fact that much of the phenotype-specific difference is lost when body mass index (BMI) indicates that adiposity might be a significant cause of high uric acid levels as opposed to phenotype. Increased uric acid in PCOS has been repeatedly linked to metabolic imbalance, such as obesity, insulin resistance, and dyslipidaemia, all of which are defining signs of metabolic syndrome, often co-morbid with PCOS.2,3 Recent population-based studies show that there is a positive relationship between hyperuricemia and PCOS, wherein PCOS patients portrayed a highly elevated prevalence of serum uric acid and hyperuricemia when compared to women with no PCOS, with mediation by metabolic variables such as hyperandrogenism, insulin resistance, and dyslipidaemia.2 Complementary studies have shown that serum uric acid quantities are positively associated with serum fructose quantities and metabolic derangements in PCOS women, suggesting multifaceted metabolism as opposed to the phenotype-specific hormonal influence.3 These results suggest that uric acid may be confounded by metabolic disturbances. Multivariate regression analyses correcting BMI, waist circumference, HOMA-IR, lipids, and other metabolic variables would be helpful in revealing whether elevated uric acid is associated with phenotype, or it is a byproduct of increased metabolic burden. I have also observed that absence of obese controls having no PCOS in the given analysis.1 I feel that a detailed clarification of metabolic confounders and interpretation of the results outside unadjusted group analyses would be beneficial to validate the clinical implications of the study.